Osteoporosis refers to excessive bone loss as reflected by the deterioration of bone mass
and microarchitecture, which compromises bone strength. It is a complex multifactorial …

Osteoporosis is a prevalent osteodegenerative disease and silent killer linked to a decrease
in bone mass and decline of bone microarchitecture, due to impaired bone matrix …

Bone loss in women commences before the onset of menopause and oestrogen deficiency.
The increase of follicle-stimulating hormone (FSH) precedes oestrogen decline and may be …

Male osteoporosis is a significant but undetermined healthcare problem. Men suffer from a
higher mortality rate post-fracture than women and they are marginalized in osteoporosis …

Abstract Chemotherapeutic agents (docetaxel, cabazitaxel), hormonal therapies
(abiraterone, enzalutamide) and radium-223 improve survival in patients with bone …

Prostate cancer (PCa) is the second leading cause of cancer‑related death among men
worldwide. The present study aimed to investigate the role of germ cell‑specific gene 2 …

Selective estrogen receptor modulators (SERMs) represent a class of drugs that act as
agonist or antagonist for estrogen receptor in a tissue-specific manner. The SERMs drugs …

Objective This article reviews the effects of androgen deprivation therapy on bone health
and loss of bone mineral density and its effects on risk of fractures for men with prostate …

Introduction: Orchidectomy is currently the preferred method to induce bone loss in
preclinical male osteoporosis model. Gonadotropin-releasing hormone (GnRH) agonists …

Dexamethasone has antitumor activity in metastatic castration resistant prostate cancer
(mCRPC). We aimed to investigate intravenous liposome‐encapsulated dexamethasone …